Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Mittelman

Showing results (41-50 of 114) with videos related to

Pageof 12
Sort By:
Plos One|January 7, 2014
Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patientsMarit M Suttorp, Tiny Hoekstra, Moshe Mittelman, et al.
Frontiers in Oncology|February 13, 2023
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, et al.
The Journal of Endocrinology|January 12, 2010
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine modelsOdelia Katz, Matthew Stuible, Nathalia Golishevski, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Pharmacoepidemiology and Drug Safety|August 13, 2015
Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural modelMarit M Suttorp, Tiny Hoekstra, Moshe Mittelman, et al.
Experimental Hematology|December 17, 2002
Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agentsSara Bar-Yehuda, Lea Madi, Dana Barak, et al.
Leukemia Research|November 22, 2016
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromesNaamit Deshet-Unger, Howard S Oster, Sara Prutchi-Sagiv, et al.
BMC Nephrology|September 27, 2013
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patientsMarit M Suttorp, Tiny Hoekstra, Joris I Rotmans, et al.
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
BMC Cancer|June 1, 2020
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myelomaEfrat Markus, Svetlana Trestman, Yael Cohen, et al.
Pageof 12

Showing results (41-50 of 114) with videos related to

Sort By:
Pageof 12
Plos One|January 7, 2014
Effect of erythropoiesis-stimulating agents on blood pressure in pre-dialysis patientsMarit M Suttorp, Tiny Hoekstra, Moshe Mittelman, et al.
Frontiers in Oncology|February 13, 2023
Lymphoid aggregates in the bone marrow biopsies of patients with myelodysplastic syndromes - A potential prognostic marker?Reut Book, Jonathan Ben-Ezra, Chen Glait Santar, et al.
The Journal of Endocrinology|January 12, 2010
Erythropoietin treatment leads to reduced blood glucose levels and body mass: insights from murine modelsOdelia Katz, Matthew Stuible, Nathalia Golishevski, et al.
International Journal of Laboratory Hematology|January 29, 2024
Validation of a novel algorithm with a high specificity in ruling out MDSFelicitas Schulz, Kathrin Nachtkamp, Howard S Oster, et al.
Pharmacoepidemiology and Drug Safety|August 13, 2015
Treatment with high dose of erythropoiesis-stimulating agents and mortality: analysis with a sequential Cox approach and a marginal structural modelMarit M Suttorp, Tiny Hoekstra, Moshe Mittelman, et al.
Experimental Hematology|December 17, 2002
Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agentsSara Bar-Yehuda, Lea Madi, Dana Barak, et al.
Leukemia Research|November 22, 2016
Erythropoietin administration is associated with improved T-cell properties in patients with myelodysplastic syndromesNaamit Deshet-Unger, Howard S Oster, Sara Prutchi-Sagiv, et al.
BMC Nephrology|September 27, 2013
Erythropoiesis-stimulating agent resistance and mortality in hemodialysis and peritoneal dialysis patientsMarit M Suttorp, Tiny Hoekstra, Joris I Rotmans, et al.
British Journal of Haematology|November 17, 2006
Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?Sara Prutchi-Sagiv, Natalia Golishevsky, Howard S Oster, et al.
BMC Cancer|June 1, 2020
Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myelomaEfrat Markus, Svetlana Trestman, Yael Cohen, et al.
Pageof 12